×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
12:53 pm
nvo
Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]
Low
Report
Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]
4/20
12:36 pm
nvo
Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]
Low
Report
Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]
4/20
12:08 pm
nvo
Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]
Low
Report
Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]
4/20
10:52 am
nvo
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]
Low
Report
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]
4/20
10:47 am
nvo
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]
Low
Report
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]
4/20
10:36 am
nvo
Agios Pharmaceuticals stock tumbles 25% after Novo data [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals stock tumbles 25% after Novo data [Yahoo! Finance]
4/20
05:36 am
nvo
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease [Yahoo! Finance]
Low
Report
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease [Yahoo! Finance]
4/20
03:42 am
nvo
Novo Nordisk Announces Partnership with OpenAI [Yahoo! Finance]
Low
Report
Novo Nordisk Announces Partnership with OpenAI [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/20
09:38 am
nvo
Form 6-K NOVO NORDISK A S For: Apr 20
Low
Report
Form 6-K NOVO NORDISK A S For: Apr 20
4/20
06:50 am
nvo
Form 6-K NOVO NORDISK A S For: Apr 20
Low
Report
Form 6-K NOVO NORDISK A S For: Apr 20
4/13
07:52 am
nvo
Form 6-K NOVO NORDISK A S For: Apr 13
Low
Report
Form 6-K NOVO NORDISK A S For: Apr 13
4/7
07:29 am
nvo
Form 6-K NOVO NORDISK A S For: Apr 07
Low
Report
Form 6-K NOVO NORDISK A S For: Apr 07
3/30
09:05 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 30
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 30
3/27
07:47 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 27
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 27
3/27
06:33 am
nvo
Form 6-K NOVO NORDISK A S For: Mar 27
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 27
3/26
01:03 pm
nvo
Form 6-K NOVO NORDISK A S For: Mar 26
Low
Report
Form 6-K NOVO NORDISK A S For: Mar 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: